Pfizer Inc demonstrates robust operations across multiple therapeutic areas, including vaccines and specialty medicines. Quarterly earnings reflect operational resilience and the company’s extensive ...

Pfizer PFE expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key products in the 2026-2030 period. These include Eliquis, Vyndaqel, Ibrance, ...

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) shares slid about 1% Tuesday morning after reports that a patient died while receiving the company's hemophilia drug Hympavzi, highlighting ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the ...

If I am a Pfizer Inc. (PFE) investor (I used to be, nonetheless), I should have been "elated" at PFE's recent performance against the market, while still getting rewarded with a forward yield that ...

Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...

The U.S. labor market showed further signs of cooling in November as nonfarm payrolls rose by 64,000, only modestly above expectations but still weak by historical standards, while the unemployment ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.